Financing led by institutional life sciences investor, with participation from new and existing investors Capital expected to support expansion of CDMO platform and advancement of customer programs April 24, 2026 -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company") a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics and the owner of Scinai Biopharma Services Ltd., a contract development and manufacturing organization (

April 22, 2026 -- Courier Health, the leading technology company for managing patient experiences, today announced it has raised a $50 million Series B funding round led by Oak HC/FT, with participation from existing investors including Norwest and Work-Bench. This latest investment will fuel continued product innovation and solidify Courier Health's position as the leading solution to orchestrate and personalize patient journeys across the life sciences industry. Despite immense clinical innov

April 21, 2026 -- Ionetix Corporation ("Ionetix"), a leading particle accelerator company focused on the medical, materials testing and nuclear energy space announced today it raised more than $30 million in a private placement offering at $3.00 per share. In addition, the company completed a go-public reverse merger transaction with JDEV Acquisition Corp., which has been renamed Ionetix Corp. Ionetix's patent-protected superconducting cyclotron technology supports unique particle accelerator s

April 17, 2026 -- MastCURe, a high-profile research consortium, has been awarded €1.3M in funding from the Eureka Eurostars program. The collaboration comprising Allegria Therapeutics, Cube Biotech, and the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP Immunology and Allergology IA aims to transform the treatment of chronic urticaria, a debilitating mast cell-driven skin disease affecting millions worldwide. MastCURe's innovative approach directly and selectively targets

Kailera Therapeutics has pulled off one of the largest biotech IPOs on record, raising $625 million as investor appetite for next-generation obesity drugs shows no signs of abating. The company priced 39.1 million shares at $16 each, which was the top end of its range. Certain existing shareholders had signaled confidence ahead of the debut, indicating plans to purchase about $225 million in the offering, or about 45% of the deal. The offering surpasses Moderna's debut in 2018 when the mRNA va

Storm Therapeutics has closed a $56 million series C financing as the British biotech kicks off a phase 2 sarcoma trial of its RNA-modifying enzyme inhibitor. Proceeds from the financing will support the mid-stage study of a METTL3 inhibitor dubbed STC-15, which is designed to reprogram malignant progenitor cells by modulating mRNA methylation, according to an April 16 release. The trial, for which the first patient has now been dosed, will assess STC-15 as a monotherapy in various sarcoma indi

Financing will support the ongoing Phase 1/2 trial of NEO-811 for the treatment of locally advanced or metastatic non-resectable clear cell renal cell carcinoma (ccRCC) and the continued advancement of the company’s broader novel molecular glue degrader pipeline April 13, 2026 -- Neomorph, Inc., a biotechnology company pioneering molecular glue degraders to address previously undruggable proteins, today announced the closing of a $100 million Series B financing. The round was led by Deerfield

Advancing next-generation RNA therapeutics beyond the liver through breakthrough delivery technologies April 10, 2026 -- Vivatides Therapeutics, a global biotechnology company focused on developing extrahepatic RNA-targeting therapeutics, announced the successful closing of an oversubscribed $54 million Series A financing. The round was co-led by Qiming Venture Partners and a leading industry fund, with participation from Highlight Capital, a leading venture fund, and TF Capital. Existing inves

A San Diego biotech looking to double up on the power of antibody-drug conjugates with fewer toxicities has patched together a $137 million Series B from a group of blue-chip investors. The seven-employee startup, called Sidewinder Therapeutics, plans to make its mark by simultaneously engaging two targets and “overcoming fundamental limitations in the first-gen ADCs,” CEO Eric Murphy said in an interview. That includes avoiding off-target toxicities that arise when ADC payloads spill into the b

It’s no secret that cancer drug development is full of bandwagons. Companies see a promising target, and crowd around it (see PD-1xVEGF or HER2 for recent examples). Aashish Manglik But two cancer biologists — Aaron Ring at the Fred Hutchinson Cancer Center and Aashish Manglik at UCSF — believed they could go one layer deeper than others. Even within a single protein target, there could be different ways for a drug to attach. They just needed a systematic way to seek out those small bits on a pr